US FDA cancels panel review for Ovation's Sabril
This article was originally published in Scrip
Executive Summary
The US FDAhas cancelled the August 6th-7th advisory panel review of Ovation's epilepsy drug Sabril (vigabatrin) because of difficulties empanelling the necessary experts owing to scheduling problems and conflicts of interest. The peripheral and central nervous system drugs panel was to consider the use of vigabatrin in two indications under priority review – adjunctive therapy for refractory partial seizures in adults and infantile spasms. Ovation previously said it anticipates receiving an action letter by the end of August and a final decision in the fourth quarter.
You may also be interested in...
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.
Preterm Birth Prevention Studies Need To Look Beyond Makena Endpoints, Experts Say
Gestational age and a binary, neonatal composite endpoint are insufficient to assess outcomes that are important to babies and families, clinicians and researchers say, suggesting development of continuous variables or scales with weighted components and a comparison of outcomes among newborns in gestational age ‘buckets.’